ArticleFrontiers in endocrinology2026
Prognostic value of admission NHHR for functional recovery in acute ischemic stroke.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Early risk stratification in acute ischemic stroke (AIS) is critical for guiding management and improving outcomes. The ratio of non-high-density lipoprotein to high-density lipoprotein cholesterol (NHHR) represents the equilibrium between pro-atherogenic and anti-atherogenic lipoproteins, potentially capturing both lipid metabolism and inflammatory status, but its prognostic value in AIS remains unclear. Methods: We retrospectively analyzed 812 first-ever AIS patients. Admission NHHR was calculated from routine lipid panels. The study's main outcome was 90-day functional status, determined using the modified Rankin Scale. Associations with NHHR were examined through multivariable logistic regression, quartile analyses, restricted cubic spline (RCS) modeling, and subgroup analyses. Results: Among 812 patients, 255 (31.4%) had unfavorable outcomes. Elevated NHHR showed an independent correlation with unfavorable 90-day functional outcomes (adjusted OR per unit increase, 1.233; 95% CI, 1.058-1.439; P = 0.0076). RCS analysis demonstrated a gradual rise in risk with increasing NHHR (P for trend = 0.043; P for nonlinearity = 0.584). Subgroup analyses showed consistent associations across sex, stroke severity, smoking, drinking, hypertension, and diabetes. Conclusion: Admission NHHR is a simple, inexpensive, and robust predictor of 90-day unfavorable outcomes in AIS. It provides a novel integrated lipid-inflammation marker for early risk stratification, warranting further validation in prospective studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.